| Literature DB >> 33779849 |
Abstract
BACKGROUND: The nightmare of the rising numbers of multidrug-resistant organisms (MDROs) requires the implementation of effective stewardship programs. However, this should be preceeded by making available evidence-based knowledge regarding the local antimicrobial resistance pattern, which is fundamental. The aim of the current study is to determine the prevalence of MDRO among different Ain Shams University Hospitals (ASUHs) intensive care units (ICUs) and detect the resistance profile of the common pathogens.Entities:
Keywords: ICU; Multidrug resistance; Egypt; Prevalence; Susceptibility profile
Year: 2021 PMID: 33779849 PMCID: PMC8007646 DOI: 10.1186/s42506-020-00065-8
Source DB: PubMed Journal: J Egypt Public Health Assoc ISSN: 0013-2446
Fig. 1Distribution of different clinical isolates among patients admitted in ICU, March 2018–February 2019
Frequency of different pathogens within various clinical specimens collected from ICU patients, Ain Shams University Hospitals, Egypt, March 2018–February 2019
| Name of organism | Total | |||
|---|---|---|---|---|
| Urine | Blood | Wound swab | ||
| 288 | 101 (35.06%) | 137 (47.56%) | 50 (17.38%) | |
| 172 | 106 (61.62%) | 48 (27.91%) | 18 (10.47%) | |
| 128 | 33 (25.78%) | 67 (52.34%) | 28 (21.88%) | |
| 114 | 49 (42.98%) | 34 (29.82%) | 31 (27.20%) | |
| 23 | 5 (21.73%) | 6 (26.10%) | 12 (52.17%) | |
| 11 | 2 (18.18%) | 8 (72.72%) | 1 (9.10%) | |
| 161 | 20 (12.42%) | 139 (86.33%) | 2 (1.25%) | |
| 151 | 74 (49.00%) | 64 (42.38%) | 13 (8.62%) | |
| 133 | 126 (94.73%) | 6 (4.51%) | 1 (%0.76) | |
| 69 | 5 (7.26%) | 46 (66.66%) | 18 (26.08%) | |
| 18 | 6 (33.33%) | 11 (61.11%) | 1 (5.56%) | |
| 12 | 3 (25.00%) | 8 (66.67%) | 1 (8.33%) | |
| 1280 | 530 (41.41%) | 574 (44.84%) | 176 (13.75%) | |
Distribution of pathogens associated with intensive care unit-associated infections and their antimicrobial resistance patterns, Ain Shams University Hospitals, Egypt, March 2018–February 2019
| Pathogen type and pattern of resistance | Resistance, | |
|---|---|---|
| 288 | ||
| ESBL production | 30 (10.4) | |
| Multidrug resistance | 253 (87.84) | |
| 128 | ||
| Multidrug resistance | 107 (83.59) | |
| 114 | ||
| Multidrug resistance | 84 (73.68) | |
| 172 | ||
| ESBL production | 80 (46.5) | |
| Multidrug resistance | 124 (72.02) | |
| 23 | ||
| ESBL production | 4 (17.4) | |
| 11 | ||
| ESBL production | 4 (36.36) | |
| 69 | ||
| MRSA | 51 (73.9) | |
| 161 | ||
| MR-CONS | 125 (77.6) | |
| 151 | ||
| VRE* | 10 (6.6) | |
| 133 | ||
| 18 | ||
| 12 | ||
| Total | 1280 |
ESBL extended-spectrum β-lactamase, MRSA methicillin-resistant S aureus, VRE vancomycin-resistant Enterococcus
*Vancomycin resistance was confirmed by Vitek 2C
Antibiotic resistance pattern of the prevalent Gram-positive pathogens isolated from patients admitted in ICU, Ain Shams University Hospitals, Egypt, March 2018-February 2019
| Antibiotic | Resistant isolates, | Total , | |||
|---|---|---|---|---|---|
34 (49.29) | 61 (37.88) | **NA | 95/230 (41.30) | 0.108 | |
NA ***67 | NA ***156 | 98 (64.90) | 321/381 (84.25) | – | |
51 (73.91) | 125 (77.63) | **NA | 176/230 (76.52) | 0.541 | |
67 (97.10) | 156 (96.89) | 118 (78.14) | 341/381 (89.50) | ||
36 (52.17) | 97 (60.2) | **NA | 133/230 (57.82) | 0.256 | |
43 (62.31) | 130 (80.74) | 147 (62.31) | 320/381 (83.98) | ||
36 (52.17) | 107 (66.45) | 131 (86.75) | 274/381 (71.91) | ||
29 (42.02) | 70 (43.47) | 38 (25.16) | 137/381 (35.95) | 0.002* | |
51 (73.91) | 98 (51.30) | **NA | 149/230 (64.78) | 0.058 | |
| **NA | **NA | 95 (62.91) | 95/151 (62.91) | – | |
0 (0) | 0 (0) | 0 (0) | 0/381 (0) | – | |
33 (47.82) | 97 (60.24) | 115 (76.15) | 245/381 (64.30) | 0.001* | |
6 (8.69) | 25 (15.52) | 26 (17.21) | 57/381 (14.96) | 0.250 | |
38 (55.07) | 76 (47.20) | 53 (35.09) | 167/381 (43.83) | 0.011* | |
40 (57.97) | 117 (72.67) | **NA | 157/230 (68.26 | 0.028* | |
10 (14.49) | 100 (62.11) | **NA | 110/230 (47.82) | ||
0 (0) | 4 (20.00) | 38 (28.12) | 42/99 (42.42) | 0.021* | |
0 (0) | 0 (0) | 10 (6.62) | 10/381 (2.62) | – | |
| No. of urine samples | 5 | 20 | 74 | 99 | |
***The resistance for ampicillin was deduced from cefoxitin
**NA = not applicable
* significant at p<0.05
Antibiotic resistance pattern of the prevalent gram-negative pathogens isolated from patients admitted in ICU, Ain Shams University Hospitals, Egypt, March 2018-February 2019
| Antibiotic | Resistant isolates, | Total , | ||||||
|---|---|---|---|---|---|---|---|---|
| 113 (88.28) | 208 (72.22) | 21 (12.21) | 76 (66.66) | 6 (26.08) | 3 (27.27) | 427/736 (58.01) | ||
| **NA | 245 (85.06) | 124 (72.09) | **NA | 12 (52.17) | 3 (27.27) | 384/494 (77.73) | ||
| 110 (85.93) | 277 (96.18) | 155 (90.11) | **NA | 14 (60.08) | 4(36.36) | 560/622 (90.03) | ||
| 110 (85.93) | 276 (96.83) | 157 (91.27) | 91 (79.82) | 7 (30.43) | 8 (72.72) | 649/736 (88.17) | ||
| 124 (96.87) | 285 (98.95) | 152 (88.37) | **NA | 12 (52.17) | 10 (90.90) | 583/622 (93.72) | ||
| **NA | 248 (86.11) | 92 (53.48) | **NA | 7 (30.43) | 10 (90.90) | 357/494 (72.26) | ||
| **NA | 282 (97.91) | 160 (93.02) | **NA | 10 (43.47) | 9 (81.81) | 461/494 (93.31) | ||
| 115 (89.84) | 279 (96.87) | 156 (90.69) | 92 (80.70) | 8 (34.78) | 10 (90.90) | 660/736 (89.67) | ||
| 127 (99.21) | 285 (98.95) | 152 (88.37) | **NA | 12 (52.17) | 10 (90.90) | 586/622 (94.21) | ||
| 111 (86.71) | 258 (89.58) | 122 (70.93) | 91 (79.82) | 13 (56.52) | 6 (54.54) | 601/736 (81.65) | ||
| 85 (66.41) | 235 (81.59) | 123 (71.51) | **NA | 19 (82.60) | 9 (81.81) | 471/622 (75.72) | 0.008* | |
| 97 (75.78) | 204 (70.83) | 66 (38.37) | 81 (71.05) | 10 (43.47) | 5 (45.45) | 463/736 (62.90) | ||
| 101 (78.91) | 225 (78.12) | 32 (18.60) | 75 (65.78) | 4 (17.39) | 3 (27.27) | 440/736 (59.78) | ||
| 109 (85.15) | 231 (80.21) | 119 (69.18) | 87 (76.31) | 14 (60.86) | 5 (45.45) | 565/736 (76.76) | 0.001* | |
| 103 (80.46) | 228 (79.16) | 34 (19.76) | 81 (71.05) | 4 (17.39) | 5 (45.45) | 455/736 (61.82) | ||
| 107 (83.59) | 250 (86.81) | 95 (55.23) | 80 (70.17) | 5 (21.73) | 10 (90.90) | 547/736 (74.32) | ||
| 114 (89.06) | 240 (83.33) | 130 (75.58) | **NA | 17 (73.91) | 3 (27.27) | 504/622 (81.02) | ||
| 90 (70.31) | 234 (81.25) | 106 (61.62) | 92 (80.70) | 6 (26.08) | 7 (63.63) | 535/736 (72.69) | ||
| 87 (67.96) | 241 (83.68) | 137 (79.65) | **NA | 16 (69.56) | 3 (27.27) | 484/622 (77.81) | ||
0 (0) | **NA | **NA | 0 (0) | **NA | **NA | **NA | – | |
| NA | 77 (76.23) | 32 (30.18) | **NA | **NA | 0 (0) | 109/209 (52.15) | ||
| No of urine samples | 33 | 101 | 106 | 49 | 5 | 2 | 296 | |
**NA = not applicable
* significant at p<0.05